Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 93.61 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • The group usually releases earnings worse than estimated.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
ABBVIE16.93%188 347
MERCK KGAA-8.06%13 246
KYOWA HAKKO KIRIN CO LTD4.77%12 454
JAZZ PHARMACEUTICALS PLC8.31%8 738
ZHANGZHOU PIENTZEHUANG PHAR..14.51%6 893
CONVATEC GROUP3.26%5 818
INDIVIOR-8.13%3 798
BETTA PHARMACEUTICALS CO LT..--.--%3 466
YUHAN CORP--.--%2 529
SUPERNUS PHARMACEUTICALS IN..-1.13%1 966
AIMMUNE THERAPEUTICS INC0.37%1 892
MALLINCKRODT PLC-28.41%1 588
REPLIGEN CORPORATION-9.07%1 384
THERAPEUTICSMD INC-9.44%1 208
ASSEMBLY BIOSCIENCES INC27.91%989
NICHI-IKO PHARMACEUTICAL CO..-1.37%971
More Results
Financials ($)
Sales 2018 32 143 M
EBIT 2018 14 063 M
Net income 2018 10 488 M
Debt 2018 22 102 M
Yield 2018 2,66%
P/E ratio 2018 17,65
P/E ratio 2019 15,28
EV / Sales 2018 6,55x
EV / Sales 2019 5,95x
Capitalization 188 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABBVIE
Duration : Period : Day
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Duration : Period : Week
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders